Myriad Genetics Statistics

Total Valuation

Myriad Genetics has a market cap or net worth of GBP 373.78 million. The enterprise value is 422.30 million.

Market Cap	373.78M
Enterprise Value	422.30M

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	92.18M
Shares Outstanding	n/a
Shares Change (YoY)	+7.09%
Shares Change (QoQ)	+0.33%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	89.78M

Valuation Ratios

PE Ratio	n/a
Forward PE	155.47
PS Ratio	0.58
PB Ratio	0.69
P/TBV Ratio	3.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.38
EV / Sales	0.69
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-22.73

Financial Position

The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.22.

Current Ratio	1.90
Quick Ratio	1.40
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	-6.57
Interest Coverage	-28.74

Financial Efficiency

Return on equity (ROE) is -13.84% and return on invested capital (ROIC) is -6.29%.

Return on Equity (ROE)	-13.84%
Return on Assets (ROA)	-5.26%
Return on Invested Capital (ROIC)	-6.29%
Return on Capital Employed (ROCE)	-10.42%
Revenue Per Employee	238,303
Profits Per Employee	-29,068
Employee Count	2,700
Asset Turnover	0.79
Inventory Turnover	9.43

Taxes

Income Tax	-19.81M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -78.12% in the last 52 weeks. The beta is 1.78, so Myriad Genetics's price volatility has been higher than the market average.

Beta (5Y)	1.78
52-Week Price Change	-78.12%
50-Day Moving Average	5.23
200-Day Moving Average	14.07
Relative Strength Index (RSI)	58.27
Average Volume (20 Days)	1,912

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.65

Income Statement

In the last 12 months, Myriad Genetics had revenue of GBP 643.42 million and -78.48 million in losses. Loss per share was -0.87.

Revenue	643.42M
Gross Profit	450.46M
Operating Income	-68.96M
Pretax Income	-98.30M
Net Income	-78.48M
EBITDA	-22.60M
EBIT	-68.96M
Loss Per Share	-0.87

Full Income Statement

Balance Sheet

The company has 71.05 million in cash and 121.98 million in debt, giving a net cash position of -50.93 million.

Cash & Cash Equivalents	71.05M
Total Debt	121.98M
Net Cash	-50.93M
Net Cash Per Share	n/a
Equity (Book Value)	545.59M
Book Value Per Share	5.92
Working Capital	105.34M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.95 million and capital expenditures -13.62 million, giving a free cash flow of -18.58 million.

Operating Cash Flow	-4.95M
Capital Expenditures	-13.62M
Free Cash Flow	-18.58M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 70.01%, with operating and profit margins of -10.72% and -12.20%.

Gross Margin	70.01%
Operating Margin	-10.72%
Pretax Margin	-15.28%
Profit Margin	-12.20%
EBITDA Margin	-3.51%
EBIT Margin	-10.72%
FCF Margin	n/a

Dividends & Yields

Myriad Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.09%
Shareholder Yield	n/a
Earnings Yield	-21.00%
FCF Yield	-4.97%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Myriad Genetics has an Altman Z-Score of 3.26 and a Piotroski F-Score of 3.

Altman Z-Score	3.26
Piotroski F-Score	3